- Home
- Products
- Customized FluoroAb™
- ERBB2
- Anti-ERBB2 MAb (Clone 12)-iFluor® 514 Succinimidyl Ester
Anti-ERBB2 MAb (Clone 12)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11131)
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; neuro/glioblastoma derived oncogene homolog (avian); NGL; v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer; stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways; such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported; with the most common allele; Ile654/Ile655; shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Humanized Anti-ERBB2 IgG1 antibody (Clone 12)
- Species Reactivity
- Human
- Name
- iFluor® 514 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 511/527
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS11131. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-1115 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1111 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1112 | Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MSLN MAb (Clone 7)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4080)
- Anti-C5 MAb (Clone 20)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS13971)
- Anti-CD6 MAb (Clone 4)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13509)
- Anti-MUC1 MAb (Clone 6)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9750)
- Anti-IFNG MAb (Clone 2)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10508)
- Anti-IL6R MAb (Clone 1)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6794)
- Anti-HIV-1 MAb (Clone 4)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS9287)
- Anti-CSF2 MAb (Clone 1)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS15575)
- Anti-CD27 MAb (Clone 2)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4697)
- Anti-CD22 MAb (Clone 27)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10108)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.